Beta Risk
Beta risk is a vital concept for anyone entering the world of stock market investing. It helps investors understand how much the overall market influences a stock or portfolio. For beginners, knowing how beta works can be extremely useful in managing investment risk, building a balanced portfolio, and setting realistic return expectations.
Table of Contents
What is Beta Risk?
Beta risk, or simply “beta,” measures how sensitive an asset’s price is to movements in the overall stock market. It specifically captures systematic risk, which is the type of risk that affects the entire market, such as economic downturns, inflation, or geopolitical instability.
In technical terms, the market (often represented by a benchmark index such as the S&P 500 or the Straits Times Index) is assigned a beta value of 1.0. A security with:
- A beta above 1.0 is considered more volatile than the market.
- A beta below 1.0 is less volatile.
- A beta of exactly 1.0 moves in line with the market.
- A negative beta suggests that the asset tends to move in the opposite direction to the market.
Importantly, beta does not capture individual or company-specific risks (known as unsystematic risk). Instead, it focuses on how an asset reacts to broader market changes.
Understanding Beta Risk
Beta risk is a tool investors use to gauge how an investment will likely behave if the market moves up or down. This is particularly helpful when deciding how to allocate assets within a diversified portfolio.
Key Characteristics of Beta:
- High Beta (>1): Indicates higher market sensitivity. Stocks like those in the tech sector often have high beta values.
- Low Beta (<1): Indicates less sensitivity to market fluctuations. Utility companies or consumer staples generally fall into this category.
- Negative Beta: Rare but sometimes seen in gold or inverse exchange-traded funds (ETFs), which may rise when the market declines.
For example, a stock with a beta of 1.3 is expected to move 13% if the market moves 10%. This means greater gains during bull markets, but also larger losses during downturns.
How is Beta Risk Calculated?
Beta is determined using statistical formulas that compare the asset’s returns with those of the market over a specific period.
Two Primary Methods:
- Covariance and Variance Method
Beta is calculated as the covariance between the asset and market returns, divided by the variance of the market returns:
Beta = Covariance (Asset, Market)/Variance (Market)
This method examines how the asset and the market move together and how volatile the market is overall.
- Linear Regression Method
This is often considered more intuitive and practical:
- A regression line is drawn plotting asset returns against market returns.
- The slope of this line represents beta.
- For example, if a regression line has a slope of 1.2, the asset is said to have a beta of 1.2.
Investors can utilize tools provided by online platforms, such as POEMS by PhillipCapital, to find pre-calculated beta values, which saves time and reduces the need for manual calculation.
Limitations of Beta Risk
While beta is a useful measure, it has its shortcomings. Relying solely on beta could lead to a misunderstanding of a stock’s actual risk.
Limitations Include:
- Backward-looking: Beta is based on past data, which may not always reflect how a stock will perform in the future.
- Non-static: A company’s beta can change over time with changes in its operations, debt levels, or market conditions.
- Ignore Specific Risks: Beta only accounts for market-related risk; it does not consider internal business problems, such as management issues or product recalls.
- Assumes Linear Relationship: Beta assumes a constant relationship between the stock and market, which is not always accurate.
- Single Market Limitation: Beta is typically measured against one market index. For companies operating globally, this may not present a full picture of their risk.
Due to these limitations, beta should be one of several tools used when evaluating risk.
Examples of Beta Risk
To better understand how beta works, let’s look at some practical, up-to-date examples from the US and Singapore markets.
Example 1: High Beta (US Tech Stock)
A leading US technology company listed on the NASDAQ has a beta of 1.6. If the S&P 500 increases by 5%, this stock is likely to increase by 8%. However, if the market falls 5%, the stock may drop by 8% or more. This behaviour makes it suitable for investors with a higher risk appetite.
Example 2: Low Beta (US Utility Company)
A large US-based utility firm has a beta of 0.4. If the S&P 500 increases by 10%, the utility stock is likely to rise by only 4%. If the market drops 10%, it may fall by only 4%. This makes such stocks attractive to conservative investors who value stability.
Example 3: Singapore REIT (Low Beta)
A Singapore-listed real estate investment trust (REIT) has a beta of 0.6 compared to the SGX index. During a volatile year when the SGX declined by 10%, the REIT declined by only 6%. This offered a more stable return pattern, which is popular among income-focused investors.
Example 4: Negative Beta Asset
An inverse ETF listed in the US, designed to move in the opposite direction of the S&P 500, may exhibit a beta of -1.0. If the market drops by 3%, the ETF may rise by 3%. Such assets can be used as hedges in downturns, but they come with higher complexity.
Frequently Asked Questions
Beta risk represents the impact of market-wide movements on an investment. In portfolio diversification, it helps investors select a combination of assets that aligns with their risk tolerance. For example, blending high-beta and low-beta assets can reduce total portfolio volatility.
By incorporating a mix of high- and low-beta assets, investors can balance risk. Low beta stocks can serve as a cushion during market downturns, while high beta stocks can enhance returns during rallies. This strategy smooths out overall performance.
No. Beta risk only refers to systematic risk- risk from market-wide factors. Total investment risk also includes unsystematic risk, which comes from individual company or sector issues. Diversification can help reduce unsystematic risk, but beta measures only the portion that cannot be diversified away.
Beta can be calculated using statistical methods like regression or covariance with variance. Interpretation is straightforward:
- Beta > 1: More volatile than the market
- Beta = 1: Same as market
- Beta < 1: Less volatile
- Beta < 0: Moves opposite to the market
Tools like financial calculators or investment platforms provide pre-calculated beta values, which are helpful for beginners.
It depends on your investment goals and risk tolerance:
- High Beta Stocks: Suitable for growth-focused investors willing to accept short-term volatility.
- Low Beta Stocks: Ideal for income-focused or risk-averse investors looking for stable returns.
For balanced portfolios, a mix of both types can offer the best of both worlds.
Related Terms
- Option Adjusted Spread (OAS)
- Bear Spread
- Execution Risk
- Exchange-Traded Notes
- Dark Pools
- Firm Order
- Covered Straddle
- Chart Patterns
- Candlestick Chart
- After-Hours Trading
- Speculative Trading
- Average Daily Trading Volume (ADTV)
- Swing trading
- Sector-Specific Basket
- Regional Basket
- Option Adjusted Spread (OAS)
- Bear Spread
- Execution Risk
- Exchange-Traded Notes
- Dark Pools
- Firm Order
- Covered Straddle
- Chart Patterns
- Candlestick Chart
- After-Hours Trading
- Speculative Trading
- Average Daily Trading Volume (ADTV)
- Swing trading
- Sector-Specific Basket
- Regional Basket
- Listing standards
- Proxy voting
- Block Trades
- Undеrmargin
- Buying Powеr
- Whipsaw
- Index CFD
- Initial Margin
- Risk Management
- Slippage
- Take-Profit Order
- Open Position
- Trading Platform
- Debit Balance
- Scalping
- Stop-Loss Order
- Cum dividend
- Board Lot
- Closed Trades
- Resistance level
- CFTC
- Open Contract
- Passive Management
- Spot price
- Trade Execution
- Spot Commodities
- Cash commodity
- Volume of trading
- Open order
- Bid-ask spread
- Economic calendar
- Secondary Market
- Subordinated Debt
- Basket Trade
- Notional Value
- Speculation
- Quiet period
- Purchasing power
- Interest rates
- Plan participant
- Performance appraisal
- Anaume pattern
- Commodities trading
- Interest rate risk
- Equity Trading
- Adverse Excursion
- Booked Orders
- Bracket Order
- Bullion
- Trading Indicators
- Grey market
- Intraday trading
- Futures trading
- Broker
- Head-fake trade
- Demat account
- Price priority
- Day trader
- Threshold securities
- Online trading
- Quantitative trading
- Blockchain
- Insider trading
- Equity Volume
- Downtrend
- Derivatives
Most Popular Terms
Other Terms
- Bond Convexity
- Compound Yield
- Brokerage Account
- Discretionary Accounts
- Industry Groups
- Growth Rate
- Green Bond Principles
- Gamma Scalping
- Funding Ratio
- Free-Float Methodology
- Foreign Direct Investment (FDI)
- Floating Dividend Rate
- Flight to Quality
- Real Return
- Protective Put
- Perpetual Bond
- Non-Diversifiable Risk
- Merger Arbitrage
- Liability-Driven Investment (LDI)
- Income Bonds
- Guaranteed Investment Contract (GIC)
- Flash Crash
- Equity Carve-Outs
- Cost of Equity
- Cost Basis
- Deferred Annuity
- Cash-on-Cash Return
- Earning Surprise
- Capital Adequacy Ratio (CAR)
- Bubble
- Asset Play
- Accrued Market Discount
- Ladder Strategy
- Junk Status
- Intrinsic Value of Stock
- Interest-Only Bonds (IO)
- Interest Coverage Ratio
- Inflation Hedge
- Industry Groups
- Incremental Yield
- Industrial Bonds
- Income Statement
- Holding Period Return
- Historical Volatility (HV)
- Hedge Effectiveness
- Flat Yield Curve
- Fallen Angel
- Exotic Options
- Event-Driven Strategy
- Eurodollar Bonds
Know More about
Tools/Educational Resources
Markets Offered by POEMS
Read the Latest Market Journal
Apple Launches First Foldable iPhone Amid Pricing and AI Challenges
Brief Overview Apple held its "Surprise and Shine" event on 9 September, launching several new products including its first foldable smartphone, the iPhone Duo. The iPhone Duo starts at US$1,999, whilst the iPhone 18 Pro and Pro Max received US$100 price increases to US$1,199 and US$1,299 respectively. Phillip Securities Research maintains a REDUCE recommendation with a raised target price of US$300, citing concerns over demand sustainability and AI execution despite expecting strong initial demand. Investment Positives The introduction of the iPhone Duo creates an entirely new price tier above the Pro Max, which should provide further support to iPhone average selling prices (ASPs). The analyst expects the new product lineup to generate strong initial demand, particularly for the iPhone Duo due to its novelty factor as Apple's first foldable smartphone. The pricing strategy across the range, including US$100 price increases for the iPhone 18 Pro and Pro Max models, is expected to strengthen the overall product mix. This has prompted the analyst to raise FY27e revenue and PATMI estimates by 1% and 2% respectively, reflecting the anticipated benefits of higher iPhone ASPs and an improved product mix following the iPhone Duo launch and Pro lineup price increases. Challenges The sustainability of demand at these increasingly premium price points remains untested and represents a key concern for the investment outlook. The analyst notes that AI remains the weaker component of Apple's investment story, with execution and adoption likely to determine whether Apple Intelligence becomes a meaningful driver of replacement cycles. Several near-term headwinds weigh on the company's prospects, including supply constraints, rising memory costs, and AI regulations. Significantly, there is currently no clear evidence that Apple Intelligence is meaningfully driving product upgrades, which undermines a key potential growth catalyst. Outlook The outlook remains complicated despite the exciting new foldable product launch. Whilst strong initial demand is expected, particularly for the innovative iPhone Duo, the combination of unproven demand sustainability at premium price points and weak AI positioning creates uncertainty. The success of the product launches will likely depend on consumer acceptance of higher pricing and the eventual effectiveness of Apple Intelligence in driving upgrade cycles. Recommendation & Target Price Phillip Securities Research maintains a REDUCE recommendation on Apple Inc. The DCF target price has been increased to US$300 from the previous US$290, based on higher expected iPhone ASPs and stronger product mix. The WACC of 6.5% and terminal growth rate of 3.5% remain unchanged. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Beyond The Usual Markets: Discover Kazakhstan
A Closer Look At Kazakhstan As Kazakhstan gains popularity as a travel destination across Central Asia, attention is slowly shifting from tourism to opportunity. What many don’t realise is that the same country attracting visitors today is also offering high-yield, under-owned investment opportunities that global markets have yet to fully price in. Most investors today are crowded into the same trades — US tech, India growth, or China recovery. But some of the most compelling opportunities are often found where few are looking. Kazakhstan is one of those markets. It is not a headline market. It is not widely covered. But that’s exactly where its opportunity lies. This article breaks down why Kazakhstan deserves a place in your portfolio — and how you can actually invest in it. Why Kazakhstan, And Why Now? Kazakhstan is the world's ninth-largest country by area, the world's largest uranium producer, and a top-ten oil exporter. Its stock exchange, Kazakhstan Stock Exchange (KASE), has quietly delivered 40% returns over the past 12 months, beating most developed and emerging markets. Yet non-residents account for just 8.3% of trading volume. The institutional wave has not arrived yet. We believe this represents a genuine early-mover window. The Astana International Financial Centre (AIFC), modelled on Dubai's DIFC and backed by a 2026–2028 strategy to attract sovereign wealth funds and global pension capital, has already channelled $21.5 billion in structured investment since inception, including $7.2 billion in 2025 alone. The infrastructure is being built to handle institutional money at scale. The question is whether your portfolio is positioned before that happens. Four Reasons This Market Stands Out The Tax Advantage: Plain And Simple Kazakhstan's tax regime for foreign investors in listed equities is one of the most favourable we have seen in any comparable market. Here is what matters most when investing through our platform. Dividends — 0% Withholding Tax (WHT) Shares that are actively traded on KASE (meeting monthly volume and transaction thresholds) qualify for a full withholding tax exemption on dividends for foreign investors. You may confirm your status with our Global Markets Desk before each position. Capital Gains — 0% For Individuals Non-resident individuals pay zero tax on capital gains from shares traded on the open market via KASE. For legal entities, gains are exempt after a 3-year holding period in non-subsoil-user companies. 53 Double-Tax Treaties Kazakhstan's double tax treaty (DTT) network covers Singapore, the US, UK, Germany, and most EU states. Investors from treaty countries benefit from further protection and potential rate reductions on non-exempt income. Tax-related information provided is for general guidance only. Please consult your tax advisor for confirmation and clarification. Five Stocks To Start With These five names represent the most liquid, transparent, and well-covered companies on KASE across five distinct sectors. Each was chosen for accessibility and suitability for investors new to the market. Risks To Keep In Mind Tenge Depreciation KZT forecast at 600–610 per USD by end-2026. At HSBK's 13% yield, the income more than offsets expected FX drag. For capital-focused positions (AIRA, KMGZ), the buffer is thinner. Oil Price Sensitivity Kazakhstan remains highly sensitive to oil prices, with crude strength supporting fiscal revenues, the tenge and KMGZ earnings. With Brent currently above USD 100/barrel, the oil-price backdrop is supportive of Kazakhstan’s macro outlook and energy sector profitability. However, a sustained reversal in crude prices would remain a key downside risk given the economy’s continued reliance on hydrocarbons. Liquidity And Order Depth Outside HSBK and KMGZ, order books can be thin. Always use limit orders on KZTO, KCEL, AIRA, and ASBN. Do not place market orders on mid-cap names — you risk moving the price against yourself before the order fills. Trade Kazakhstan With POEMS Kazakhstan-listed shares are now available for online trading through POEMS. Trading Hours (SGT) Pre-Opening Session 2:20PM – 2:30PM Main Continuous Session 2:30PM – 8:30PM For more information, visit POEMS or contact our Global Markets Desk at talktoglobalmarkets@phillip.com.sg. Make Kazakhstan Part Of Your Global Market View Explore Kazakhstan on POEMS and discover opportunities across KASE. Trade Kazakhstan Open An Account Now! DisclaimerDisclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Keppel DC REIT Strengthens Japan Expansion with Major Tokyo Data Centre Acquisition
Brief Overview Keppel DC REIT (KDCREIT) has agreed to jointly acquire a 90% effective interest in two hyperscale data centres in Greater Tokyo for JPY190 billion (S$1,549 million). The acquisition is expected to be 2.6% accretive to FY25 pro-forma distribution per unit (DPU) and will significantly deepen the REIT's Japan presence. The properties offer contractual rent escalation of 2.8% per annum and are under-rented by at least 30%. Investment Positives The acquisition presents multiple compelling growth drivers for long-term income expansion. Tokyo Data Centre 4 and 5 are freehold colocation facilities that are 100% occupied by four investment-grade clients, providing strong tenant quality and full occupancy rates. The properties offer a balanced risk-return profile with a blended weighted average lease expiry (WALE) of 8.3 years, combining reversion opportunities with long-term income visibility. The deal provides substantial embedded rental upside potential, with in-place rents under-rented by at least 30% and contracted average annual rent escalation of approximately 2.8%. More than 5% of rents are due for renewal by 2029, creating near-term reversion opportunities. The acquisition was secured at a 2.1% discount to the properties' valuation of JPY194 billion, representing attractive pricing. Strategically, the acquisition strengthens KDCREIT's position in one of Asia Pacific's most attractive data centre markets. Japan's contribution to portfolio rental income will increase significantly from approximately 9% as at 30 June 2026 to approximately 23% post-acquisition. The properties are located in Inzai City, one of Japan's most established hyperscale data centre clusters. Japan's market fundamentals support long-term growth prospects, underpinned by rising cloud adoption, AI-related deployments and digital transformation. Structural supply constraints, including power constraints, construction bottlenecks and land scarcity, should further enhance the market's growth potential. Investment Negatives The acquisition will increase aggregate leverage from 34% to 38%, representing a meaningful increase in the REIT's debt levels. The financing structure requires a substantial private placement to raise at least S$600 million, which will increase the unit base by approximately 12%, creating dilution for existing unitholders. The acquisition is scheduled to complete in 4Q26, meaning investors will need to wait for the benefits to materialise. Outlook The transaction combines immediate DPU accretion with multiple avenues for long-term income growth. Japan's favourable demand-supply dynamics should support continued growth, while the portfolio's asset under management is expected to grow to S$7.6 billion from S$6.3 billion. Recommendation & Target Price Phillip Securities Research maintains an ACCUMULATE recommendation with an unchanged target price of S$2.46. The analysts have yet to update their financials for the acquisition and private placement but remain positive on the deal's strategic value and accretive nature. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Geo Energy Resources Ltd – De-risked, ready to rumble
Brief Overview Geo Energy Resources delivered 1H26 results within expectations, with revenue and net profit representing 36% and 37% respectively of full-year forecasts. The company's US$190 million integrated infrastructure project has been completed and operational since July, whilst production declined 42% year-on-year to 3.8 million tonnes as operations shift to the new infrastructure. The sales target for FY26 remains unchanged at 11.5-12.5 million tonnes. Investment Positives The completion and operational status of Geo's integrated infrastructure represents a significant milestone for the company. The 92-kilometre hauling road and jetty facility, held through 69.9% subsidiary Marga Bara Jaya (MBJ), has a substantial capacity of 25 million tonnes and went live operationally in July. This development is expected to drive meaningful production improvements, with Geo anticipated to transport 4 million tonnes of coal through MBJ in 2H26, rising to 11 million tonnes in FY27. The infrastructure's excess capacity creates additional revenue streams through toll and jetty fees supported by multi-year contracts. Production capabilities are set to enhance further as 2x70MT trucks arrive in September to replace the current 40MT fleet, supporting operational ramp-up. Looking ahead to FY27, analysts forecast production to surge 40% to 17 million tonnes whilst cash costs are expected to decline. The coal price environment also provides tailwinds, with prices up 53% year-on-year in 3Q26. Gross margins improved to 18.9% from 15.6% previously, supported by a 16.5% rise in average selling prices to US$529 per tonne. Investment Negatives The primary concern centres on the significant production decline in 1H26, where output fell 42% year-on-year to 3.8 million tonnes. This reduction stems from deliberate delays in TRA production ramp-up as the company transitions coal transportation from the existing Atlas road to its proprietary MBJ infrastructure. Additionally, TBR pit boundary expansion due to high wall pushback contributed to operational disruptions, with TBR production dropping 51% to 2 million tonnes. Cash costs increased 12.5% to US$40.6 per tonne, attributed to higher fuel prices, which pressured operational margins during the transition period. Outlook With the integrated infrastructure now operational, Geo's earnings visibility has been substantially de-risked. FY27 represents a milestone year with forecast production growth of 40% and declining cash costs, supported by infrastructure fee income from multi-year contracts and favourable coal price trends. Recommendation & Target Price Phillip Securities Research maintains a BUY recommendation with an unchanged DCF target price of S$0.75. The FY26 earnings forecast remains unchanged following the results. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
NVIDIA Corporation – Strong Growth Driven by AI Infrastructure Demand
Brief Overview NVIDIA delivered 2Q27 results within expectations, with data centre revenue surging 117% year-on-year to US$89bn. The company guided FY28e revenue growth of about 70% year-on-year, though this is constrained by supply factors. Phillip Securities Research maintains a BUY rating with a raised target price of US$300. Investment Positives Hyperscale revenue showed significant acceleration in 2Q27, growing 102% year-on-year to US$48.7bn, compared to 93% growth in 1Q27. This acceleration was driven by hyperscalers increasing capital expenditure spending on GPU capacity, particularly for Blackwell Ultra. The top four hyperscalers - Google, Amazon, Microsoft, and Meta - increased their 2026e capital expenditure guidance by 5% this quarter to US$748bn, representing 97% year-on-year growth. NVIDIA expects their total capital expenditure to reach US$1.3tn in 2027e, reflecting 74% year-on-year growth. Amazon is deploying an additional 2 million of NVIDIA's GPUs until 2Q29e, whilst Microsoft announced plans to modernise its infrastructure with NVIDIA's Vera Rubin, which commenced shipments in August. The AI Clouds, Industrial & Enterprise (ACIE) segment recorded the fastest growth, with 2Q27 revenue spiking 138% year-on-year, overtaking hyperscale growth rates. This growth was supported by significant contract wins, including AI startups Reflection and Cohere signing multi-year contracts worth US$1bn or more with Nebius for AI workloads running on NVIDIA-powered infrastructure. Sovereign AI revenue more than tripled year-on-year, with substantial partnerships announced. NVIDIA partnered with Noetra, Japan's national AI company, to deploy 13,750 Vera CPUs and 27,500 Rubin GPUs delivering 140MW of AI compute for physical AI. South Korea committed to invest at least US$3bn for NVIDIA and Hyundai to deploy 50,000 Blackwell GPUs for AI model training and deployment. Investment Negatives The report indicates that rising memory costs present a headwind to NVIDIA's margins, which prompted the analyst to raise the weighted average cost of capital to 8.4% from 7.9%. Supply constraints including land, power, shell, and cooling are limiting NVIDIA's revenue growth potential. Without these constraints, demand could grow more than 100% in FY28e, compared to the guided 70% growth. Outlook Global semiconductor spending surged 108% year-on-year in 1H2026 to US$675bn, driven by hyperscaler, enterprise, and sovereign nations' AI buildout. The analyst raised FY27e revenue and PATMI forecasts by 11% due to stronger expected growth from the ACIE segment and rapid Vera Rubin ramp in 2H27e. Recommendation & Target Price Phillip Securities Research maintains a BUY recommendation with a raised target price of US$300, increased from the previous US$285. NVIDIA trades at a FY27e price-to-earnings ratio of 24x, representing a 32% discount to peers' average of 35x. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Salesforce Inc – The End of the SaaSpocalypse
Brief Overview Salesforce delivered mixed second quarter results with revenue meeting expectations but profit after tax and minority interest (PATMI) lagging due to higher research and development and sales & marketing spending. The company is positioning itself as the enterprise AI data layer through Headless and Claudeforce initiatives, extending CRM data into platforms like Claude, Slack and Teams. Management anticipates second half growth driven by premium AI products and usage-based monetisation, with significant growth potential as only 5% of users currently use higher-tier editions. Investment Positives The core Sales and Service Cloud divisions continue to demonstrate resilience as revenue anchors. Revenue increased 11% year-on-year to US$11.3 billion, maintaining consistent growth momentum from the previous quarter's 10% increase. The sales division faces minimal AI disruption since monetisation primarily occurs through upselling existing Salesforce offerings. Customer retention metrics remain exceptionally strong with attrition near record lows, whilst Sales, Service and Slack all delivered seat growth. Existing customers are actively upgrading through premium AI-enabled bundles, particularly Agentforce 1 Edition for premium Sales and Service Cloud. Agentforce application bookings have also more than doubled quarter-on-quarter, whilst premium Slack upgrades tripled following Slackbot's March 2026 launch. The agentic AI momentum continues to accelerate significantly. Agentforce annual recurring revenue exceeded US$1.5 billion, representing approximately 3.3% of FY27 revenue guidance midpoint and marking growth of more than 240% year-on-year. The consumption-based pricing model encourages rapid customer adoption, with Agentforce bookings doubling quarter-on-quarter. Notably, 50% of new bookings came from existing customers purchasing additional credits after initial deployment. Growth products including Agentforce, Headless and Data 360 collectively reached nearly US$3.9 billion in annual recurring revenue. Salesforce benefits from owning crucial customer data, workflows, permissions and governance layers that support data quality, whilst customers increasingly prefer AI embedded within existing software rather than managing complex internal AI systems. Investment Negatives The report identifies higher research and development, marketing and sales expenses as factors contributing to lower-than-expected earnings performance. These increased operational costs resulted in PATMI lagging behind revenue performance during the quarter. Outlook Management expects second half growth to be driven by premium AI products including Agentforce, Slackbot and Claudeforce, alongside usage-based monetisation and customer upgrades. The growth runway remains substantial given that only 5% of users currently utilise higher-tier editions. Recommendation & Target Price Phillip Securities Research maintains a NEUTRAL recommendation whilst raising the DCF target price to US$243 from the previous US$166. The analysts increased their terminal growth rate from 3% to 5.5%, reflecting improved market confidence in Salesforce's core CRM business, the Anthropic Claudeforce partnership, and stronger software sector sentiment as enterprise AI monetisation gains traction. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Thomson Medical Group Ltd Shows Turnaround Progress Despite Volume Challenges
Brief Overview Thomson Medical Group delivered FY26 results largely in line with expectations, with revenue and EBITDA meeting 97% and 98% of forecasts respectively. The company experienced earnings recovery across all three operating countries - Singapore, Malaysia, and Vietnam - with EBITDA expanding 21% year-on-year in the second half to S$43.6mn. Growing revenue intensity has driven earnings improvements, though currency headwinds affected results. Investment Positives The primary positive driver for Thomson Medical has been the significant growth in average bill size across all three operating markets. Singapore recorded the largest increase in average bill size at 421.8%, driven by a combination of increased case complexity and a higher product mix as procedures were shifted to outpatient day surgery. Malaysia also benefited from improved revenue intensity, with average bill size growing 111.9%. This improvement was supported by oncology and gastroenterology cases, alongside the return of some insurance payers. The Malaysian operations saw EBITDA expand 34.6% as the business rebuilds its insurance relationships. Vietnam demonstrated strong operational momentum with inpatient volumes increasing 46.5% and average bill size growing 2.1%. The Vietnamese operations benefited from higher volumes including robotic surgery procedures and increased capacity, resulting in EBITDA growth of 52.4%. The group's strategic pivot away from Singapore's historical reliance on obstetrics and gynaecology cases is showing results, with the addition of more orthopaedics, ENT and general surgery procedures improving the revenue mix. Investment Negatives The key challenge facing Thomson Medical is declining volumes across the group. Total inpatient volumes fell 7.8% year-on-year to 39,000 patients in FY26. Singapore experienced a 9% decline in inpatient volumes, primarily due to lower delivery cases in obstetrics. Malaysia recorded an 11.5% drop in inpatient volumes, which the analyst attributes to the absence of insurance payers. Finance costs continue to weigh on earnings despite a 16.5% reduction due to lower interest rates. The company also recorded a S$15.2mn goodwill impairment due to a higher discount rate assumption. Outlook The analyst views Thomson Medical as successfully executing its operational turnaround strategy. The company is effectively diversifying Singapore away from obstetrics cases whilst Malaysia rebuilds its insurance partnerships with foreign patients and oncology leading increased revenue intensity. However, finance costs remain a burden on earnings performance. Recommendation & Target Price Phillip Securities Research has upgraded Thomson Medical to BUY due to recent share price performance. The target price remains unchanged at S$0.071 using a sum-of-the-parts valuation approach. The analyst maintained FY27e earnings forecasts while rolling over valuations to FY27e earnings. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
iX Biopharma Ltd – Galloping Closer with Partners
Brief Overview iX Biopharma's FY26 results fell below expectations, with revenue and net loss at 72% and 170% of forecast respectively. The US$40.9mn Wafermine Programme from the US Department of Defense has commenced, with the company recognising S$1.2mn as development services. The analyst expects revenue to triple in FY27e, driven by compounding pharmacy operations, Wafermine sales, and development services. Investment Positives The primary investment driver centres on the Wafermine development programme, which is just beginning to gain momentum. Since receiving the Department of Defense award in February, approximately four months of development work have been completed. The analyst expects revenue to climb significantly as more development work for Emergency Use Authorisation (EUA) and Phase 3 trials is undertaken. The company has secured substantial funding through the US$40.9mn Wafermine Programme, which will finance both Phase 3 and EUA development activities. This programme has already started generating revenue, with S$1.2mn recognised as development services in the current period. Revenue diversification is expected to strengthen the business model, with three key growth drivers anticipated for FY27e: the compounding pharmacy operations with partner Orion Speciality, Wafermine sales, and continued development services revenue. The company also benefited from currency movements, with other gains of S$2.1mn resulting from the strengthening of the Australian dollar against the Singapore dollar. Investment Negatives Operating expenses were significantly higher than anticipated, presenting a key challenge for the company. The main contributors were a S$2.08mn share performance plan (non-cash) and S$1mn in one-off professional fees related to securing the Department of Defense funding contract. However, excluding these items, operating expenses remained largely stable. General and administrative expenses increased by 58%, primarily due to the S$2mn performance share plan. Research and development costs also rose by 52% to S$2.5mn. The transfer of equipment from Australia to the United States resulted in lower medicinal cannabis sales, with approximately S$3mn in lost revenue. Cannabis sales specifically declined by 46% to S$3.5mn, contributing to the overall revenue shortfall. Outlook The analyst has incorporated higher upfront costs from US wholesale compounding pharmacy operations and increased performance shares into updated forecasts. Key milestones ahead include the Wafermine EUA submission in 4Q26, EUA approval in 1Q27, EUA production in 2Q27, and Phase 3 trials approval in 2Q27. The US production line is expected to commence in 1Q27, with three additional lines starting in 2Q27. Recommendation & Target Price Phillip Securities Research maintains a BUY recommendation with an unchanged DCF SOTP target price of S$1.00. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
